Sagan Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -14.80%
(FY 2020)
- Profit 107.86%
(FY 2020)
- Ebitda -34.05%
(FY 2020)
- Net Worth 72.10%
(FY 2020)
- Total Assets 9.26%
(FY 2020)
About Sagan Pharma
The Corporate was formerly known as Sagan Pharmacy Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Tumpa Chowdhury, Amarnath Kumar, and Smriti Manjari serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC281048
- Company No.
281048
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 May 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sagan Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tumpa Chowdhury  | Director | 06-Jun-2017 | Current |
| Amarnath Kumar | Director | 13-May-2016 | Current |
| Smriti Manjari | Additional Director | 08-May-2023 | Current |
Financial Performance of Sagan Pharma.
Sagan Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 14.8% decrease. The company also saw a substantial improvement in profitability, with a 107.86% increase in profit. The company's net worth Soared by an impressive increase of 72.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sagan Pharma?
In 2019, Sagan Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sagan Diagnostics Private LimitedActive 2 years 6 monthsTumpa Chowdhury and Amarnath Kumar are mutual person
- Sagan Media Private LimitedActive 12 years 5 months
Amarnath Kumar and Smriti Manjari are mutual person
- Wrap Data Private LimitedActive 7 years 11 months
Amarnath Kumar and Smriti Manjari are mutual person
- Kavrin Events Private LimitedActive 14 years 16 days
Amarnath Kumar and Smriti Manjari are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sagan Pharma?
Unlock and access historical data on people associated with Sagan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sagan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sagan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
